Pharvaris (NASDAQ:PHVS) Earns Buy Rating from HC Wainwright

Pharvaris (NASDAQ:PHVS)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $60.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 154.78% from the company’s previous close. HC Wainwright also issued estimates for Pharvaris’ Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.70) EPS, FY2025 earnings at ($3.28) EPS, Q2 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($0.90) EPS, FY2026 earnings at ($3.38) EPS, FY2027 earnings at ($2.64) EPS and FY2029 earnings at $2.19 EPS.

PHVS has been the subject of a number of other reports. Zacks Research raised Pharvaris from a “strong sell” rating to a “hold” rating in a research report on Monday, August 18th. JMP Securities reduced their price objective on Pharvaris from $55.00 to $52.00 and set a “market outperform” rating for the company in a research note on Wednesday, August 13th. Bank of America upgraded shares of Pharvaris from an “underperform” rating to a “neutral” rating and raised their target price for the stock from $16.00 to $27.00 in a research report on Thursday, October 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a report on Wednesday, October 8th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Pharvaris presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.57.

Pharvaris Stock Performance

NASDAQ:PHVS opened at $23.55 on Thursday. Pharvaris has a fifty-two week low of $11.51 and a fifty-two week high of $26.33. The company has a 50 day moving average price of $23.20 and a 200 day moving average price of $20.65. The stock has a market capitalization of $1.23 billion, a P/E ratio of -7.34 and a beta of -2.78.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Wednesday, November 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.08. Research analysts forecast that Pharvaris will post -2.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in PHVS. Palumbo Wealth Management LLC raised its position in shares of Pharvaris by 3.2% in the 2nd quarter. Palumbo Wealth Management LLC now owns 14,549 shares of the company’s stock valued at $256,000 after purchasing an additional 447 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares in the last quarter. HighVista Strategies LLC lifted its position in Pharvaris by 4.3% in the second quarter. HighVista Strategies LLC now owns 23,739 shares of the company’s stock worth $418,000 after purchasing an additional 971 shares during the period. California State Teachers Retirement System lifted its holdings in shares of Pharvaris by 9.8% in the second quarter. California State Teachers Retirement System now owns 14,048 shares of the company’s stock valued at $247,000 after buying an additional 1,257 shares during the period. Finally, Legal & General Group Plc boosted its position in shares of Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after purchasing an additional 1,695 shares in the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.